Venous Ulcers

Varithena® improves the underlying symptoms of C5/C6 venous disease.


With Varithena® you can treat the symptoms of the underlying problem. As an FDA approved Microfoam UDSS™ Procedure, Varithena® can go where wire-based ablation devices cannot. Varithena® can treat the veins that feed the ulcer and address the underlying venous incompetence above and below the knee.12,13

Before & After Photos

These photos show results after one treatment with Varithena®.
Additional treatment may be needed, depending on the number and size of veins to be treated.
Your results may vary

  • Varithena® is indicated for the treatment of the great saphenous vein (GSV) system above and below the knee.
  • Varithena® treats the underlying venous insufficiency associated with C6 venous disease
  • Varithena® has shown positive outcomes improving symptoms in C5/C6 patients12
  • Varithena® has an established safety profile for the C2-C6 population in clinical trials

To learn more about how Varithena works, view this video.

Did you know?

  • 1 in 4 Americans 65+ will suffer from C6 venous disease in their lifetime12
  • Costs each patient $17k-$23k annually13
  • Costs the healthcare system $10B+ annually13
  • Up to 70% of C6 venous ulcers recur 3 months after healing14

“The impact of a C5/C6 venous disease represents social, personal, financial and psychological costs on the individual and further economic drain on the health-care system.14


Contact your
Territory Sales Manager

Contact Customer Service at

1-855-971-VEIN (8346)

Monday through Friday,
8 am to 5 pm ET


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

This website is intended for visitors from the United States.